<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated">
      <PMID Version="1">29773275</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1532-1770</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>31</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2017</Year>
              <Month>Aug</Month>
            </PubDate>
          </JournalIssue>
          <Title>Best practice &amp; research. Clinical rheumatology</Title>
          <ISOAbbreviation>Best Pract Res Clin Rheumatol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Periodic fever syndromes.</ArticleTitle>
        <Pagination>
          <StartPage>596</StartPage>
          <EndPage>609</EndPage>
          <MedlinePgn>596-609</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.berh.2017.12.001</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1521-6942(17)30100-6</ELocationID>
        <Abstract>
          <AbstractText>Periodic fever syndromes are autoinflammatory diseases. The majority present in infancy or childhood and are characterised by recurrent episodes of fever and systemic inflammation that occur in the absence of autoantibody production or identifiable infection. The best recognised disorders include CAPS, FMF, TRAPS and MKD. Understanding the molecular pathogenesis of these disorders provides unique insights into the regulation of innate immunity. Diagnosis relies on clinical acumen and is supported by genetic testing. With the exception of FMF, which is prevalent in populations originating from the Mediterranean, these syndromes are rare and easily overlooked in the investigation of recurrent fevers. Disease severity varies from mild to life threatening, and one of the most feared complications is AA amyloidosis. Effective therapies are available for many of the syndromes, including colchicine, IL-1 blockade and anti-TNF therapies, and there is an increasing interest in blocking interferon pathways.</AbstractText>
          <CopyrightInformation>Crown Copyright Â© 2017. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lachmann</LastName>
            <ForeName>Helen J</ForeName>
            <Initials>HJ</Initials>
            <AffiliationInfo>
              <Affiliation>National Amyloidosis Centre and Centre for Acute Phase Proteins, Division of Medicine, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK. Electronic address: h.lachmann@ucl.ac.uk.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>01</Month>
          <Day>11</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Best Pract Res Clin Rheumatol</MedlineTA>
        <NlmUniqueID>101121149</NlmUniqueID>
        <ISSNLinking>1521-6942</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>SML2Y3J35T</RegistryNumber>
          <NameOfSubstance UI="D003078">Colchicine</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C536657">Periodic fever, familial, autosomal dominant</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003078" MajorTopicYN="N">Colchicine</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056587" MajorTopicYN="N">Cryopyrin-Associated Periodic Syndromes</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010505" MajorTopicYN="N">Familial Mediterranean Fever</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005334" MajorTopicYN="N">Fever</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D056660" MajorTopicYN="Y">Hereditary Autoinflammatory Diseases</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Aphthous stomatitis</Keyword>
        <Keyword MajorTopicYN="Y">Blau syndrome</Keyword>
        <Keyword MajorTopicYN="Y">Chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature syndrome (CANDLE)</Keyword>
        <Keyword MajorTopicYN="Y">Cryopyrin-associated periodic syndromes (CAPS)</Keyword>
        <Keyword MajorTopicYN="Y">Deficiency of IL-1 receptor antagonist (DIRA)</Keyword>
        <Keyword MajorTopicYN="Y">Deficiency of IL-36 receptor antagonist (DITRA)</Keyword>
        <Keyword MajorTopicYN="Y">Deficiency of adenosine deaminase 2 (DADA2)</Keyword>
        <Keyword MajorTopicYN="Y">Familial Mediterranean fever (FMF)</Keyword>
        <Keyword MajorTopicYN="Y">Mevalonate kinase deficiency (MKD)</Keyword>
        <Keyword MajorTopicYN="Y">Pharyngitis and cervical adenitis (PFAPA)</Keyword>
        <Keyword MajorTopicYN="Y">Tumour necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS)</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>10</Month>
          <Day>31</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>5</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29773275</ArticleId>
        <ArticleId IdType="doi">10.1016/j.berh.2017.12.001</ArticleId>
        <ArticleId IdType="pii">S1521-6942(17)30100-6</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
